← Back to Search

Local Anesthetic

Tetracaine Drops and Phenol for Hearing Loss

Q: What afflictions are commonly treated with Tetracaine?

Moderate and persistent cases of <a href="https://www.withpower.com/clinical-trials/psoriasis">psoriasis</a> can be managed with tetracaine. The medication may also prove to be beneficial for other ailments, including exanthema, mild throat inflammation, and minor burns.

Q: What is the current enrollment size for this clinical trial?

Affirmative. Clinicaltrials.gov cites that this medical trial is presently enrolling patients since its initial posting on 8/1/2021, with the latest update occurring on 9/20/2022. The study seeks 80 volunteers from a single location.

Q: Are there precedent studies that have utilized Tetracaine?

Currently, 5 clinical trials for Tetracaine are being conducted. One of these studies is in the third and final phase. The majority of testing sites are situated in Scottsdale, <a href="https://www.withpower.com/clinical-trials/arizona">Arizona</a>; however, there are also 4 other locations where this medication can be tested.

Q: Are there still opportunities for participants to join this experiment?

The information hosted on clinicaltrials.gov indicates that this trial is still recruiting patients, with the initial post posted on August 1st 2021 and the latest update being made September 20th 2022.

Our Lady of the Lake Hospital, Baton Rouge, LA

Targeting 3 different conditionsPhenol 90% concentration +1 morePhase < 1Waitlist AvailableResearch Sponsored by Our Lady of the Lake Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adult subjects (18 years of age or greater)

Diagnosed with Idiopathic Sudden Sensorineural hearing loss or Meniere's disease

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Upimmediately following the procedure to 6 months from procedure

Awards & highlights

No Placebo-Only Group

Study Summary

This trial is testing whether or not a numbing drop (tetracaine) is more effective and less painful than a numbing agent applied directly to the eardrum (phenol) for people getting a steroid injection into the ear for Meniere's disease or idiopathic sudden sensorineural hearing loss.

Eligible Conditions

Intratympanic Steroid Injection
Sudden Sensorineural Hearing Loss
Meniere's Disease

Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

Select...

You must be 18 years old or older to participate.

Select...

You have been diagnosed with sudden hearing loss or Meniere's disease.

Select...

Your treatment plan involves getting a steroid injection in your ear.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ immediately following the procedure to 6 months from procedure

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~immediately following the procedure to 6 months from procedure

This trial's timeline: 3 weeks for screening, Varies for treatment, and immediately following the procedure to 6 months from procedure for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Difference in Pain Score

Secondary outcome measures

Statistical difference in tympanic membrane perforation presence or absence after the steroid injection procedure when using either tetracaine or phenol as the local anesthetic

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Active Control

Group I: TetracaineActive Control1 Intervention

Patients will be positioned in supine position at this time 0.5% tetracaine drops will be used to fill the ear canal. Tetracaine will then be allowed to stay in place for approximately 10 to 15 minutes with the patient's head positioned with affected ear up. After this, using an operative microscope the drops will be removed from the ear canal with suction.

Group II: PhenolActive Control1 Intervention

Patients will be positioned in supine position and tympanic membrane visualized with operative microscope. Phenol applicator will be used to topically apply 90% phenol to the injection site (posterior/Inferior aspect of tympanic membrane).

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Our Lady of the Lake HospitalLead Sponsor

12 Previous Clinical Trials

759 Total Patients Enrolled

Louisiana State University Health Sciences Center - New OrleansUNKNOWN

1 Previous Clinical Trials

440 Total Patients Enrolled

Media Library

Tetracaine 5% drops (Local Anesthetic) Clinical Trial Eligibility Overview. Trial Name: NCT04794842 — Phase < 1

Intratympanic Steroid Injections Research Study Groups: Tetracaine, Phenol

Intratympanic Steroid Injections Clinical Trial 2023: Tetracaine 5% drops Highlights & Side Effects. Trial Name: NCT04794842 — Phase < 1

Tetracaine 5% drops (Local Anesthetic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04794842 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What afflictions are commonly treated with Tetracaine?

"Moderate and persistent cases of psoriasis can be managed with tetracaine. The medication may also prove to be beneficial for other ailments, including exanthema, mild throat inflammation, and minor burns."

Answered by AI

What is the current enrollment size for this clinical trial?

"Affirmative. Clinicaltrials.gov cites that this medical trial is presently enrolling patients since its initial posting on 8/1/2021, with the latest update occurring on 9/20/2022. The study seeks 80 volunteers from a single location."

Answered by AI

Are there precedent studies that have utilized Tetracaine?

"Currently, 5 clinical trials for Tetracaine are being conducted. One of these studies is in the third and final phase. The majority of testing sites are situated in Scottsdale, Arizona; however, there are also 4 other locations where this medication can be tested."

Answered by AI

Are there still opportunities for participants to join this experiment?

"The information hosted on clinicaltrials.gov indicates that this trial is still recruiting patients, with the initial post posted on August 1st 2021 and the latest update being made September 20th 2022."

Answered by AI